Press
Releases

Press Releases

May 7, 2024
Altimmune to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md. , May 07, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: JMP Life Sciences
May 1, 2024
Altimmune to Participate at Two Upcoming Conferences
GAITHERSBURG, Md. , May 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris , Chief Medical Officer at Altimmune, will present on behalf of the Company at the following two upcoming conferences: BTIG Obesity
April 25, 2024
Altimmune Statement on the Passing of Dr. Stephen Harrison
GAITHERSBURG, Md. , April 25, 2024 (GLOBE NEWSWIRE) -- The Altimmune team would like to express our sorrow and extend our heartfelt condolences to Dr. Stephen Harrison’s family following his tragic and unexpected passing. Dr. Harrison’s countless contributions to advancing needed treatments for
 

Investor Contact

Richard Eisenstadt
Chief Financial Officer

Email: reisenstadt@altimmune.com

 

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe